These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

950 related articles for article (PubMed ID: 18456496)

  • 21. The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
    Du Y; Zhou Q; Yin W; Zhou L; Di G; Shen Z; Shao Z; Lu J
    Breast Cancer Res Treat; 2011 Oct; 129(3):839-48. PubMed ID: 21809115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Classical lobular breast carcinoma consistently lacks topoisomerase-IIα gene amplification: implications for the tailored use of anthracycline-based chemotherapies.
    Brunello E; Brunelli M; Manfrin E; Nottegar A; Bersani S; Vergine M; Molino A; Fiorio E; Chilosi M; Gobbo S; Martignoni G; Bonetti F
    Histopathology; 2012 Feb; 60(3):482-8. PubMed ID: 22168383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
    Knoop AS; Knudsen H; Balslev E; Rasmussen BB; Overgaard J; Nielsen KV; Schonau A; Gunnarsdóttir K; Olsen KE; Mouridsen H; Ejlertsen B;
    J Clin Oncol; 2005 Oct; 23(30):7483-90. PubMed ID: 16234514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
    Chen S; Huang L; Liu Y; Chen CM; Wu J; Shao ZM
    Eur J Surg Oncol; 2013 Jun; 39(6):619-26. PubMed ID: 23473851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
    Arpino G; Ciocca DR; Weiss H; Allred DC; Daguerre P; Vargas-Roig L; Leuzzi M; Gago F; Elledge R; Mohsin SK
    Breast Cancer Res Treat; 2005 Jul; 92(1):69-75. PubMed ID: 15980993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
    Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
    Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
    Tinari N; Lattanzio R; Natoli C; Cianchetti E; Angelucci D; Ricevuto E; Ficorella C; Marchetti P; Alberti S; Piantelli M; Iacobelli S
    Clin Cancer Res; 2006 Mar; 12(5):1501-6. PubMed ID: 16533774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
    Bartlett JM; Munro A; Cameron DA; Thomas J; Prescott R; Twelves CJ
    J Clin Oncol; 2008 Nov; 26(31):5027-35. PubMed ID: 18768436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of HER-2 and Topoisomerase IIalpha in response to primary doxorubicin in breast cancer.
    Arriola E; Moreno A; Varela M; Serra JM; Falo C; Benito E; Escobedo AP
    Eur J Cancer; 2006 Nov; 42(17):2954-60. PubMed ID: 16935488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y; Booser DJ; Sneige N
    Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?
    Di Leo A; Biganzoli L; Claudino W; Licitra S; Pestrin M; Larsimont D
    Eur J Cancer; 2008 Dec; 44(18):2791-8. PubMed ID: 18993056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy.
    Martin-Richard M; Muñoz M; Albanell J; Colomo L; Bellet M; Rey MJ; Tabernero J; Alonso C; Cardesa A; Gascon P; Fernandez PL
    Oncology; 2004; 66(5):388-94. PubMed ID: 15331926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
    Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M;
    Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
    Ellis MJ; Tao Y; Young O; White S; Proia AD; Murray J; Renshaw L; Faratian D; Thomas J; Dowsett M; Krause A; Evans DB; Miller WR; Dixon JM
    J Clin Oncol; 2006 Jul; 24(19):3019-25. PubMed ID: 16754938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
    Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic strategies in male breast cancer: clinical implications of chromosome 17 gene alterations and molecular subtypes.
    Schildhaus HU; Schroeder L; Merkelbach-Bruse S; Binot E; Büttner R; Kuhn W; Rudlowski C
    Breast; 2013 Dec; 22(6):1066-71. PubMed ID: 24080492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy.
    Junker K; Stachetzki U; Rademacher D; Linder A; Macha HN; Heinecke A; Müller KM; Thomas M
    Lung Cancer; 2005 Apr; 48(1):59-67. PubMed ID: 15777971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topoisomerase 2 alpha and the case for individualized breast cancer therapy.
    Glynn RW; Miller N; Whelan MC; Kerin MJ
    Ann Surg Oncol; 2010 May; 17(5):1392-7. PubMed ID: 20217261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.